Lung Deposition of Tanimilast, an Inhaled Phosphodiesterase-4 Inhibitor, in Patients with Asthma or COPD, Evaluated Using Functional Respiratory Imaging.

Navid Monshi Tousi¹, Romina Osello², Debora Santoro³, Laura Campochiaro², Jason H T Bates⁴, Dmitry Galkin³, Jan De Backer⁵, Hosein Sadafi¹, Gwen Skloot³

¹FLUIDDA NV, Kontich, Belgium.

²Global Technical Development, Chiesi Farmaceutici SpA, Parma, Italy.

³Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.

⁴University of Vermont, Burlington, Vermont, USA.

⁵FLUIDDA Inc., New York, New York, USA.

PubMed DOI

Abstract

BACKGROUND: Tanimilast is a novel phosphodiesterase-4 inhibitor under clinical development for the maintenance therapy of asthma and chronic obstructive pulmonary disease (COPD). Since tanimilast is inhaled, it is important to evaluate lung deposition as part of its clinical development. The current study, therefore, used functional respiratory imaging, a validated, noninvasive quantification imag…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.